Hanwei Yin

842 total citations
23 papers, 678 citations indexed

About

Hanwei Yin is a scholar working on Molecular Biology, Nutrition and Dietetics and Oncology. According to data from OpenAlex, Hanwei Yin has authored 23 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 5 papers in Nutrition and Dietetics and 4 papers in Oncology. Recurrent topics in Hanwei Yin's work include Redox biology and oxidative stress (12 papers), Glutathione Transferases and Polymorphisms (10 papers) and Selenium in Biological Systems (5 papers). Hanwei Yin is often cited by papers focused on Redox biology and oxidative stress (12 papers), Glutathione Transferases and Polymorphisms (10 papers) and Selenium in Biological Systems (5 papers). Hanwei Yin collaborates with scholars based in China, United States and Taiwan. Hanwei Yin's co-authors include Huihui Zeng, Debabrata Chakravarti, J. Brandon Parker, Qiang Tan, Ruoxuan Sun, Jing Li, Xiaoqing Zheng, Kun Xiong, Jianing Fu and Lihui Wang and has published in prestigious journals such as The Journal of Immunology, Molecular and Cellular Biology and Scientific Reports.

In The Last Decade

Hanwei Yin

23 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hanwei Yin China 15 436 131 126 96 96 23 678
Eli Oldham United States 2 452 1.0× 96 0.7× 57 0.5× 119 1.2× 45 0.5× 7 757
Edwin C. Chinje United Kingdom 13 337 0.8× 74 0.6× 55 0.4× 94 1.0× 36 0.4× 16 638
Mark A. Montoya United States 14 387 0.9× 117 0.9× 68 0.5× 87 0.9× 26 0.3× 17 602
Lena Schultz United States 11 363 0.8× 100 0.8× 33 0.3× 61 0.6× 48 0.5× 18 617
Praveen Rajendran United States 17 907 2.1× 141 1.1× 31 0.2× 152 1.6× 60 0.6× 38 1.1k
Uddhav P. Kelavkar United States 14 291 0.7× 96 0.7× 109 0.9× 50 0.5× 69 0.7× 25 653
Steve Perry United States 13 337 0.8× 112 0.9× 78 0.6× 34 0.4× 43 0.4× 18 737
Rafał R. Siciński United States 17 282 0.6× 297 2.3× 139 1.1× 94 1.0× 22 0.2× 84 1.3k
Míriam Tarrado‐Castellarnau Spain 10 438 1.0× 60 0.5× 33 0.3× 178 1.9× 28 0.3× 13 664
Yukiko Honda United States 9 604 1.4× 147 1.1× 17 0.1× 58 0.6× 80 0.8× 12 743

Countries citing papers authored by Hanwei Yin

Since Specialization
Citations

This map shows the geographic impact of Hanwei Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanwei Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanwei Yin more than expected).

Fields of papers citing papers by Hanwei Yin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanwei Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanwei Yin. The network helps show where Hanwei Yin may publish in the future.

Co-authorship network of co-authors of Hanwei Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Hanwei Yin. A scholar is included among the top collaborators of Hanwei Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanwei Yin. Hanwei Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chang, Yuanhao, Jin Chang, Jing Sun, et al.. (2025). Novel Thioredoxin reductase 1 inhibitor BS1801 relieves treatment resistance and triggers endoplasmic reticulum stress by elevating reactive oxygen species in glioma. Redox Biology. 86. 103827–103827. 2 indexed citations
2.
Su, Xiaoxia, Hanwei Yin, Jiayi Liu, et al.. (2023). A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti–PD-1 Immunotherapy against Hepatocarcinoma. The Journal of Immunology. 210(5). 681–695. 9 indexed citations
3.
Chen, Yifan, Hanwei Yin, Jing Sun, et al.. (2023). TrxR/Trx inhibitor butaselen ameliorates pulmonary fibrosis by suppressing NF-κB/TGF-β1/Smads signaling. Biomedicine & Pharmacotherapy. 169. 115822–115822. 8 indexed citations
4.
Yang, Cheng, Hanwei Yin, Yang Chen, et al.. (2023). Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats. Molecules. 28(24). 8102–8102. 2 indexed citations
5.
Tian, Qianqian, et al.. (2022). Quantification of the major circulating metabolite of BS1801, an ebselen analog, in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 212. 114638–114638. 5 indexed citations
6.
Wu, Xuping, et al.. (2021). Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Scientific Reports. 11(1). 6069–6069. 14 indexed citations
7.
Yin, Hanwei, Jiayi Liu, Jing Sun, et al.. (2021). Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway. Frontiers in Molecular Biosciences. 8. 690170–690170. 9 indexed citations
8.
Peng, Wei, Yuejiao Zhong, Yan Sun, et al.. (2019). Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer. Scientific Reports. 9(1). 19084–19084. 28 indexed citations
9.
Chen, Xiaofeng, Yi Yao, Yueqin Li, et al.. (2019). Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study. Scientific Reports. 9(1). 2652–2652. 23 indexed citations
10.
Zheng, Xiaoqing, Wei Xu, Ruoxuan Sun, et al.. (2017). Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells. Chemico-Biological Interactions. 275. 74–85. 26 indexed citations
11.
Zheng, Xiaoqing, Ruoxuan Sun, Hanwei Yin, et al.. (2017). Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biology. 14. 237–249. 52 indexed citations
12.
Dong, Chaoran, Lei Zhang, Ruoxuan Sun, et al.. (2016). Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress. Scientific Reports. 6(1). 36860–36860. 39 indexed citations
13.
Parker, J. Brandon, et al.. (2014). Host Cell Factor-1 Recruitment to E2F-Bound and Cell-Cycle-Control Genes Is Mediated by THAP11 and ZNF143. Cell Reports. 9(3). 967–982. 42 indexed citations
14.
Wang, Lei, Jianing Fu, Jingyu Wang, et al.. (2011). Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anti-Cancer Drugs. 22(8). 732–740. 29 indexed citations
15.
Wang, Lihui, Zhiyu Yang, Jianing Fu, et al.. (2011). Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radical Biology and Medicine. 52(5). 898–908. 126 indexed citations
16.
17.
18.
Chen, Julia Ling-Yu, Daniel Merl, Christopher W. Peterson, et al.. (2010). Lactic Acidosis Triggers Starvation Response with Paradoxical Induction of TXNIP through MondoA. PLoS Genetics. 6(9). e1001093–e1001093. 107 indexed citations
19.
Tan, Qiang, Jing Li, Hanwei Yin, et al.. (2009). Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Investigational New Drugs. 28(3). 205–215. 37 indexed citations
20.
Lan, Linxiang, Fang Zhao, Jing Li, et al.. (2008). A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells. Journal of Zhejiang University SCIENCE B. 9(1). 16–21. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eli Oldham Breakdown of academic impact, for papers by Edwin C. Chinje Breakdown of academic impact, for papers by Mark A. Montoya Breakdown of academic impact, for papers by Lena Schultz Breakdown of academic impact, for papers by Praveen Rajendran Breakdown of academic impact, for papers by Uddhav P. Kelavkar Breakdown of academic impact, for papers by Steve Perry Breakdown of academic impact, for papers by Rafał R. Siciński Breakdown of academic impact, for papers by Míriam Tarrado‐Castellarnau Breakdown of academic impact, for papers by Yukiko Honda
Rankless by CCL
2026